An interventional study of Biomarker measurement of pannexin-1 and gasdermin-D in Pregnancy Complications and Maternal Obesity, sponsored by Haseki Training and Research Hospital. Completed at 1 site in Turkey. Open to female participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Haseki Training and Research Hospital · Not applicable, Interventional, and Basic science
One -third of fertile women around the world are overweight or obese. This means increasing risk for both the mother and the child. Fat tissue is a factor in gestational DM development and the increase in material inflammation and oxidative stress. According to new knowledge, it is an important need to examine molecules that are not handled in new and human research in these mechanisms in fat and placenta tissues in obesity. For this purpose, the examination of the expression of gasdermin-D and pannex-1 proteins, which are shown to be produced in the cells of both tissues, is worth investigating in human fat tissue and placenta. Gasdermins and pannexins are proteins intersecting by interacting in cellular functions.
Gasdermins cause piroptosis, a type of litic proinflammatory cell death. Pannexin-1 plays in various cellular functions, including inflammation. These are examined in a small number of in vitro studies in material fat tissue and placenta, and the design of this study in people whose applications are applied is original in humans.
The status of the expressions of the gasdermin-D and pannexin-1 proteins, which will be examined for the first time in obese pregnant women's fat and placental tissues, are the subject of this research with each other and their relationship with other maternal and neonatal data.
437 studies on the registry are indexed under Pregnancy Complications; 119 are open to participants now.
This study's enrollment of 79 is below the median of 147 across 220 interventional studies indexed under Pregnancy Complications.
Browse Pregnancy Complications studies →Haseki Training and Research Hospital is the lead sponsor of 75 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The women who had term pregnancy and had normal BMI.
Diagnostic Test: Biomarker measurement of pannexin-1 and gasdermin-D
The women who had term pregnancy and had BMI values between 25-30.
Diagnostic Test: Biomarker measurement of pannexin-1 and gasdermin-D
The women who had term pregnancy, and had BMI values more than 30.
Diagnostic Test: Biomarker measurement of pannexin-1 and gasdermin-D
These biomarkers were measured in the placental and adipose tissues of the participants.
Prediction of macrosomy
Prediction of macrosomy will be assesed by meaningfull increases of studied biomarkers Gasdermin-D and Pannexin-1
Time frame: 7 months
Plan to share: No
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haseki Training and Research Hospital